VYGR Stock Analysis: Buy, Sell, or Hold?
VYGR - Voyager Therapeutics, Inc. Common Stock
$3.86
-0.01 (-0.26%)
▼
5d:
-1.53%
30d:
-6.99%
90d:
-4.46%
BUY
HIGH Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When VYGR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: VYGR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: VYGR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: VYGR is currently trading at $3.86, which is considered slightly low relative to its 30-day fair value range of $3.72 to $4.42.
Technical Outlook: Technically, VYGR is showing sideways momentum. Immediate support is located at $3.65, while resistance sits at $4.22.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.89 (+285.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VYGR is showing sideways momentum. Immediate support is located at $3.65, while resistance sits at $4.22.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.89 (+285.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$3.72 -
$4.42
Company Quality Score
48/100
(HOLD)
Options IV Signal
25th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 25th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 285.7% below Wall St target ($14.89)
Fair Price Analysis
30-Day Fair Range
$3.72 -
$4.42
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.48
(12.4%)
Support & Resistance Levels
Support Level
$3.65
Resistance Level
$4.22
Current Trend
Sideways
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.25
Wall Street Target
$14.89
(+285.7%)
Revenue Growth (YoY)
144.3%
Profit Margin
-296.5%
Share & Embed Analysis
Last updated: March 31, 2026 5:55 PM ET
Data refreshes hourly during market hours. Next update: 6:55 PM
Data refreshes hourly during market hours. Next update: 6:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYGR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Alfred Sandrock
SELL
14197 shares
2026-02-24
Nathan D Jorgensen
SELL
4668 shares
2026-02-24
Robin Swartz
SELL
6458 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 60 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 50 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 47 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 55 HOLD |
